GOCL Corporation Regulatory Approval

Acquisition

GOCL Corporation Acquisition

GOCL Corporation Limited issued a notice for an NCLT-convened meeting of equity shareholders on November 24, 2026, to approve the proposed merger of HNPCL.

Financial Results

GOCL Corporation Q2 FY27 Results: Net Profit ₹40.5 Cr, Up 189.3% YoY

GOCL Corporation Ltd reported revenue from operations of ₹4.1 Cr (+86.4% YoY) and net profit of ₹40.5 Cr (+189.3% YoY) for Q2 FY27.

Key figure

Net profit ₹40.5 Cr · +189.3% YoY

Board Meeting Date

GOCL Corporation Board Meeting Date

GOCL Corporation Ltd scheduled a board meeting on October 19, 2026, to approve the un-audited financial results for the quarter and half-year ended September 30, 2026.

Acquisition

GOCL Corporation Acquisition

GOCL Corporation Limited received an NCLT order directing shareholder and creditor meetings to consider the proposed merger with Hinduja National Power Corporation Limited.

Other Announcement

GOCL Corporation Other Announcement

GOCL Corporation Ltd filed its quarterly shareholding pattern as per SEBI regulations. This is a routine compliance disclosure detailing the company's shareholding structure.

Annual General Meeting

GOCL Corporation Annual General Meeting

GOCL Corporation Limited held its 65th Annual General Meeting on September 29, 2026. Shareholders considered financial statements, dividend declaration for FY 2025-26, and director re-appointments.

Regulatory ApprovalWanbury Ltd WANBURYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Wanbury Regulatory Approval

Wanbury received ANVISA (Brazil FDA) CADIFA approval for Metformin HCl EP grade API, its third consecutive ANVISA clearance. The company has initiated customer talks to increase API volumes in Brazil.

Regulatory ApprovalSandur Manganese & Iron Ores Ltd SANDUMAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sandur Manganese & Iron Ores Regulatory Approval

Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.

iron ore RoM capacity

9.42 MTPA

Regulatory ApprovalNeogen Chemicals Ltd NEOGENAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Regulatory ApprovalArihant Capital Markets Ltd ARIHANTCAPAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Regulatory ApprovalDr. Reddy's Laboratories Ltd DRREDDYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.